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============

We deeply appreciate the great contributions of many physicians in the registry of esophageal cancer cases. The Comprehensive Registry of Esophageal Cancer in Japan, 2010, was published here, despite some delay. The registry complies with the Act for the Protection of Personal Information. The encryption with a HASH function is used for ''anonymity in an unlinkable fashion''.

We briefly summarized the Comprehensive Registry of Esophageal Cancer in Japan, 2010. Japanese Classification of Esophageal Cancer 10th and UICC TNM Classification 7th were used for cancer staging according to the subjected year. A total of 5878 cases were registered from 280 institutions in Japan. Tumor locations were cervical: 4.3%, upper thoracic: 12.7%, middle thoracic: 48.8%, lower thoracic: 26.5% and EG junction: 6.5%. Superficial carcinomas (Tis, T1a, T1b) were 34.9%. As for the histologic type of biopsy specimens, squamous cell carcinoma and adenocarcinoma accounted for 90.5 and 4.0%, respectively. Regarding clinical results, the 5-year survival rates of patients treated using endoscopic mucosal resection, concurrent chemoradiotherapy, or esophagectomy were 85.5, 27.3, and 55.5%, respectively. Esophagectomy was performed in 3564 cases. Concerning the approach used for esophagectomy, 30.4% of the cases were treated thoracoscopically. The operative mortality (within 30 days after surgery) was 0.61% and the hospital mortality was 4.29%.

We hope that this Comprehensive Registry of Esophageal Cancer in Japan for 2010 will help to improve all aspects of the diagnosis and treatment of esophageal cancer in Japan.
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I. Clinical factors of esophageal cancer patients treated in 2010 {#Sec3}
=================================================================

Institution-registered cases in 2010 {#Sec4}
------------------------------------

InstitutionAichi Cancer CenterAichi Medical University HospitalAizawa HospitalAkita Kouseiren Hiraka HospitalAkita University HospitalArao Municipal HospitalAsahikawa Medical College HospitalChiba Aoba Municipal HospitalChiba Cancer CenterChiba Medical CenterChiba Prefectural Sawara HospitalChiba University HospitalChibaken Saiseikai Narashino HospitalDokkyo Medical University HospitalEhime University HospitalFoundation for Detection of Early Gastric CarcinomaFuchu HospitalFujioka General HospitalFujisawa Shounandai HospitalFujita Health UniversityFukui Prefectural HospitalFukui University HospitalFukuoka Dental College and Dental HospitalFukuoka Saiseikai General HospitalFukuoka University Chikushi HospitalFukuoka University HospitalFukuoka Wajiro HospitalFukushima Medical University HospitalFukuyama City HospitalFussa HospitalGifu Prefectural General Medical CenterGifu University HospitalGunma Central General HospitalGunma Prefectural Cancer CenterGunma University HospitalGunmaken Saiseikai Maebashi HospitalHachinohe City HospitalHakodate Goryokaku HospitalHakodate National HospitalHamamatsu University School of Medicine, University HospitalHannan Chuo HospitalHeartlife HospitalHigashiosaka City General HospitalHiratsuka City HospitalHiratsuka Kyosai HospitalHirosaki University HospitalHiroshima City Asa HospitalHiroshima University Research Institute for Radiation Biology MedicineHofu Institute of GastroenterologyHokkaido Kin-Ikyo Chuo HospitalHokkaido University HospitalHyogo Cancer CenterHyogo College of MedicineHyogo Prefectural Nishinomiya HospitalIbaraki Prefectural Central HospitalIizuka HospitalIkeda Municipal HospitalImazu Surgical ClinicInazawa City HospitalInternational University of Health and Welfare HospitalInternational University of Health and Welfare, Mita HospitalIsehara Kyodo HospitalIshikawa Prefectural Central HospitalIwakuni Medical CenterIwate Medical University HospitalIwate Prefectural Chubu HospitalJapanese Red Cross Fukui HospitalJapanese Red Cross Ishinomaki HospitalJapanese Red Cross Kyoto Daini Hospital?Japanese Red Cross Maebashi HospitalJapanese Red Cross Nagaoka HospitalJapanese Red Cross Okayama HospitalJapanese Red Cross Society Azumino HospitalJapanese Red Cross Tottori HospitalJichi Medical University HospitalJuntendo University HospitalJuntendo University Shizuoka HospitalJunwakai Memorial HospitalKagawa Prefectural Central HospitalKagawa Rosai HospitalKagawa University HospitalKagoshima Kenritsu Satsunan HospitalKagoshima University HospitalKameda General HospitalKanagawa Cancer CenterKanazawa Medical University HospitalKanazawa University HospitalKansai Medical University Hirakata HospitalKansai Medical University Medical CenterKansai Rosai HospitalKasamatsu HospitalKashiwa Kousei General HospitalKawakita General HospitalKawasaki Medical School HospitalKawasaki Medical School Kawasaki HospitalKawasaki Municipal Ida HospitalKeio University HospitalKeiyukai Sapporo HospitalKikuna Memorial HospitalKinki Central HospitalKinki University HospitalKiryu Kosei General HospitalKishiwada City HospitalKitaakita Municipal HospitalKitakyushu Municipal Medical CenterKitano HospitalKobe City Medical Center General HospitalKobe University HospitalKochi Health Science CenterKochi University HospitalKokura Memorial HospitalKumamoto City HospitalKumamoto University HospitalKurashiki Central HospitalKurume General HospitalKurume University HospitalKyoto University HospitalKyushu Central Hospital of the Mutual Aid Association of Public School TeachersKyushu HospitalKyushu Medical CenterKyushu University HospitalMachida Municipal HospitalMatsuda HospitalMatsushita Memorial HospitalMatsuyama Red Cross HospitalMie University HospitalMino City HospitalMito Red Cross HospitalMitsui Memorial HospitalMiyazaki Konan HospitalMurakami General HospitalMusashino Red Cross HospitalNagahama City HospitalNagano Red Cross HospitalNagaoka Chuo General HospitalNagasaki University HospitalNagayoshi General HospitalNagoya City University HospitalNagoya City West Medical CenterNagoya Daiichi Red Cross HospitalNagoya University HospitalNanpuh HospitalNara Hospital Kinki University Faculty of MedicineNara Medical University HospitalNational Cancer Center HospitalNational Cancer Center Hospital EastNational Defense Medical College HospitalNational Hospital Organization Beppu Medical CenterNational Hospital Organization Chiba-East-HospitalNational Hospital Organization Fukuoka-Higashi Medical CenterNational Hospital Organization Iwakuni Medical CenterNational Hospital Organization Kure Medical CenterNational Hospital Organization Kyoto Medical CenterNational Hospital Organization Kyushu Cancer CenterNational Hospital Organization Matsumoto National HospitalNational Hospital Organization Nagasaki Medical CenterNational Hospital Organization Nagoya Medical CenterNational Hospital Organization Osaka National HospitalNational Hospital Organization Tokyo Medical CenterNiigata Cancer Center HospitalNiigata City General HospitalNiigata Prefectural Shibata HospitalNiigata University Medical and Dental HospitalNikko Memorial HospitalNippon Medical School Chiba Hokusoh HospitalNippon Medical School HospitalNippon Medical School Musashi Kosugi HospitalNippon Medical School Tama Nagayama HospitalNishi-Kobe Medical CenterNishinomiya Municipal Central HospitalNumazu City HospitalObihiro Kousei General HospitalObitsusankei HospitalOhta General Hospital Foundation Ohta Nishinouchi HospitalOita Red Cross HospitalOita University HospitalOkayama Saiseikai General HospitalOkayama University HospitalOmuta City HospitalOsaka City University HospitalOsaka Hospital of Japan Seafarers Relief AssociationOsaka Medical Center for Cancer and Cardiovascular DiseasesOsaka Medical College HospitalOsaka Police HospitalOsaka Prefectural Hospital Organization Osaka General Medical CenterOsaka University HospitalOtsu Municipal HospitalOtsu Red Cross HospitalRinku General Medical CenterRyukyu University HospitalSaga-ken Medical Center KoseikanSaiseikai Fukushima General HospitalSaiseikai Hiroshima HospitalSaiseikai Kyoto HospitalSaiseikai Yahata General HospitalSaitama Cancer CenterSaitama City HospitalSaitama Medical CenterSaitama Medical University HospitalSaitama Medical University Saitama International Medical CenterSaitama Medical University Saitama Medical CenterSakai City Medical CenterSaku Central HospitalSanin Rosai HospitalSano Kousei General HospitalSendai City HospitalSendai Medical CenterShiga Medical Center for AdultsShiga University of Medical Science HospitalShikoku Cancer CenterShimada HospitalShimane University HospitalShimizu Welfare HospitalShinshu University HospitalShizuoka Cancer CenterShizuoka City Shizuoka HospitalShizuoka General HospitalShowa University Fujigaoka HospitalShowa University HospitalShowa University Koto-Toyosu HospitalShowa University Northern Yokohama HospitalSocial Insurance Omuta Tenryo HospitalSocial Insurance Tagawa HospitalSt. Marianna University School of Medical HospitalSt. Luke's International HospitalSugita Genpaku Memorial Obama Municipal HospitalSuita Municipal HospitalTakasago Municipal HospitalTakatsuki Red Cross HospitalTakeda HospitalTeikyo University HospitalTeikyo University Hospital, MizonokuchiTenri HospitalThe Cancer Institute Hospital of JFCRThe Jikei University HospitalThe Research Center Hospital for Charged Particle Therapy of NIRSTochigi Medical CenterToho University Omori Medical CenterToho University Sakura Medical CenterTohoku Kosai HospitalTohoku University HospitalTokai University HospitalTokushima Municipal HospitalTokushima Prefectural Naruto HospitalTokushima Red Cross HospitalTokushima University HospitalTokyo Dental College Ichikawa General HospitalTokyo Medical and Dental University HospitalTokyo Medical University HospitalTokyo Medical University Ibaraki Medical CenterTokyo Metropolitan Health and Medical Corporation Toshima HospitalTokyo University HospitalTokyo Women's Medical University HospitalTokyo Women's Medical University Medical Center EastTonan HospitalToranomon HospitalTottori Prefectural Central HospitalTottori University HospitalToyama Prefectural Central HospitalToyama University HospitalToyonaka Municipal HospitalTsuchiura Kyodo HospitalTsukuba University HospitalTsuruoka Municipal Shonai HospitalUniversity Hospital, Kyoto Prefectural University of MedicineUniversity of Miyazaki HospitalWakayama Medical University HospitalYamagata Prefectural and Sakata Municipal Hospital OrganizationYamagata Prefectural Central HospitalYamagata Prefectural Shinjo HospitalYamaguchi University HospitalYamaguchi-ken Saiseikai Shimonoseki General HospitalYamanashi Prefectural Central HospitalYamanashi University HospitalYao Municipal HospitalYokohama Chuo HospitalYokohama City Municipal HospitalYokohama City University HospitalYokohama City University Medical CenterYuri General Hospital(Total 280 institutions)

**Patient background** {#Sec5}
----------------------

###### 

Age and gender

  Age       Male   Female   Unknown   Cases (%)
  --------- ------ -------- --------- --------------
  ≤29       1      1                  2 (0.0%)
  30--39    14     4                  18 (0.3%)
  40--49    125    44                 169 (2.9%)
  50--59    802    145      1         948 (16.1%)
  60--69    2140   291      1         2432 (41.4%)
  70--79    1596   267                1863 (31.7%)
  80--89    342    78                 420 (7.1%)
  ≥90       8      7                  15 (0.3%)
  Unknown   10     1                  11 (0.2%)
  Total     5038   838      2         5878

###### 

Primary treatment

  Treatments                  Cases (%)
  --------------------------- --------------
  Surgery                     3638 (61.9%)
   Esophagectomy              3564 (60.6%)
   Palliative                 74 (1.3%)
  Chemotherapy/radiotherapy   1413 (24.0%)
  Endoscopic treatment        827 (14.1%)
  Total                       5878

###### 

Tumor location

  Location of tumor   Endoscopic treatment (%)   Surgery        Chemotherapy and/or radiotherapy (%)   Total (%)     
  ------------------- -------------------------- -------------- -------------------------------------- ------------- --------------
  Cervical            18 (2.2%)                  116 (3.3%)     6 (8.1%)                               114 (8.1%)    254 (4.3%)
  Upper thoracic      90 (10.9%)                 411 (11.5%)    15 (20.3%)                             233 (16.5%)   749 (12.7%)
  Middle thoracic     483 (58.4%)                1669 (46.8%)   39 (52.7%)                             677 (47.9%)   2868 (48.8%)
  Lower thoracic      186 (22.5%)                1054 (29.6%)   12 (16.2%)                             303 (21.4%)   1555 (26.5%)
  EG                  34 (4.1%)                  241 (6.8%)     1 (1.4%)                               31 (2.2%)     307 (5.2%)
  E = G               1 (0.1%)                   38 (1.1%)      1 (1.4%)                               1 (0.1%)      41 (0.7%)
  GE                  3 (0.4%)                   27 (0.8%)                                             6 (0.4%)      36 (0.6%)
  Unknown             12 (1.5%)                  8 (0.2%)                                              48 (3.4%)     68 (1.2%)
  Total               827                        3564           74                                     1413          5878

*E* esophageal, *G* gastric

###### 

Histologic types of biopsy specimens

  Histologic types             Cases (%)
  ---------------------------- --------------
  Squamous cell carcinoma      5320 (90.5%)
   Squamous cell carcinoma     3581 (60.9%)
   Well differentiated         334 (5.7%)
   Moderately differentiated   1072 (18.2%)
   Poorly differentiated       333 (5.7%)
  Adenocarcinoma               233 (4.0%)
  Barrett's adenocarcinoma     64 (1.1%)
  Adenosquamous carcinoma      8 (0.1%)
  Mucoepidermoid carcinoma     2 (0.0%)
  Basaloid carcinoma           27 (0.5%)
  Endocrine cell carcinoma     13 (0.2%)
  Undifferentiated carcinoma   10 (0.2%)
  Sarcoma                      2 (0.0%)
  Malignant melanoma           16 (0.3%)
  Carcinosarcoma               9 (0.2%)
  GIST                         1 (0.0%)
  Other tumors                 34 (0.6%)
  Unknown                      139 (2.4%)
  Total                        5878

###### 

Depth of tumor invasion, cT (UICC TNM 7th)

  cT        Cases (%)
  --------- --------------
  cTX       16 (0.3%)
  cT0       9 (0.2%)
  cTis      144 (2.4%)
  cT1a      780 (13.3%)
  cT1b      1130 (19.2%)
  cT2       813 (13.8%)
  cT3       2134 (36.3%)
  cT4a      357 (6.1%)
  cT4b      410 (7.0%)
  Unknown   85 (1.4%)
  Total     5878

###### 

Lymph node metastasis, cN (UICC TNM 7th)

  cN        Cases (%)
  --------- --------------
  cNX       88 (1.5%)
  cN0       2646 (45.0%)
  cN1       1642 (27.9%)
  cN2       986 (16.8%)
  cN3       342 (5.8%)
  Unknown   174 (3.0%)
  Total     5878

###### 

Distant metastasis, cM (UICC TNM 7th)

  cM        Cases (%)
  --------- --------------
  cM0       5091 (86.6%)
  cM1       652 (11.1%)
  Unknown   135 (2.3%)
  Total     5878

###### 

Clinical Stage (UICC TNM 7th)

  Clinical stage   Endoscopic treatment (%)   Surgery       Chemotherapy and/or radiotherapy (%)   Total (%)     
  ---------------- -------------------------- ------------- -------------------------------------- ------------- --------------
  0                112 (13.5%)                12 (0.3%)                                            1 (0.1%)      125 (2.1%)
  IA               563 (68.1%)                862 (24.2%)                                          158 (11.2%)   1583 (26.9%)
  IB               4 (0.5%)                   299 (8.4%)    2 (2.7%)                               68 (4.8%)     373 (6.3%)
  IIA              2 (0.2%)                   336 (9.4%)    7 (9.5%)                               49 (3.5%)     394 (6.7%)
  IIB              2 (0.2%)                   378 (10.6%)   2 (2.7%)                               64 (4.5%)     446 (7.6%)
  IIIA             7 (0.8%)                   783 (22.0%)   12 (16.2%)                             165 (11.7%)   967 (16.5%)
  IIIB             5 (0.6%)                   354 (9.9%)    13 (17.6%)                             92 (6.5%)     464 (7.9%)
  IIIC             25 (3.0%)                  241 (6.8%)    22 (29.7%)                             315 (22.3%)   603 (10.3%)
  IV               31 (3.7%)                  145 (4.1%)    12 (16.2%)                             409 (28.9%)   597 (10.2%)
  Unknown          76 (9.2%)                  154 (4.3%)    4 (5.4%)                               92 (6.5%)     326 (5.5%)
  Total            827                        3564          74                                     1413          5878

II. Results of endoscopically treated patients in 2010 {#Sec6}
======================================================

###### 

Details of endoscopic treatment

  Treatment details   Cases (%)
  ------------------- -------------
  EMR                 59 (7.8%)
  EMR + YAG laser     6 (0.8%)
  ESD                 667 (88.5%)
  ESD + EMR           6 (0.8%)
  ESD + PDT           4 (0.5%)
  ESD + YAG laser     1 (0.1%)
  PDT                 3 (0.4%)
  YAG laser           8 (1.1%)
  Total               754

*EMR* endoscopic mucosal resection, *ESD* endoscopic submucosal dissection, *YAG* yttrium aluminum garnet, *PDT* photodynamic therapy

###### 

Complications of EMR/ESD

  Complications of EMR/ESD   Cases (%)
  -------------------------- -------------
  None                       672 (90.4%)
  Perforation                13 (1.7%)
  Bleeding                   2 (0.3%)
  Mediastinitis              4 (0.5%)
  Stenosis                   44 (5.9%)
  Others                     8 (1.1%)
  Total                      743

###### 

Pathological depth of tumor invasion of EMR/ESD specimens

  Pathological depth of tumor invasion (pT)   Cases (%)
  ------------------------------------------- -------------
  pTX                                         1 (0.1%)
  pT0                                         7 (0.9%)
  pTis                                        163 (21.9%)
  pT1a                                        482 (64.9%)
  pT1b                                        74 (10.0%)
  pT2                                         1 (0.1%)
  Unknown                                     15 (2.0%)
  Total                                       743

III. Results in patients treated with chemotherapy and/or radiotherapy in 2010 {#Sec7}
==============================================================================

###### 

Dose of irradiation (non-surgically treated cases)

  Dose of irradiation (Gy)   Definitive          Palliative (%)     Recurrence (%)     Others (%)          Unknown (%)        Total (%)           
  -------------------------- ------------------- ------------------ ------------------ ------------------- ------------------ ------------------- -------------------
  ≤29                        5 (2.9%)            10 (1.4%)          26 (9.2%)                              1 (2.7%)                               42 (3.5%)
  30--39                     1 (0.6%)            7 (1.0%)           43 (15.1%)         3 (10.0%)           4 (10.8%)                              58 (4.8%)
  40--49                     9 (5.3%)            24 (3.5%)          36 (12.7%)         1 (3.3%)            10 (27.0%)                             80 (6.6%)
  50--59                     27 (15.9%)          173 (25.0%)        60 (21.1%)         9 (30.0%)           13 (35.1%)         1 (33.3%)           283 (23.3%)
  60--69                     124 (72.9%)         453 (65.5%)        109 (38.4%)        17 (56.7%)          9 (24.3%)          2 (66.7%)           714 (58.7%)
  ≥70                        4 (7.2%)            14 (2.1%)          5 (0.0%)                                                                      23 (2.2%)
  Unknown                                        11 (1.6%)          5 (1.8%)                                                                      16 (1.3%)
  Total                      170                 692                284                30                  37                 3                   1216
  Median (min--max)          60.0 (2.0--105.0)   60.0 (1.8--72.0)   52.5 (1.8--90.0)   60.0 (37.5--67.0)   50.0 (9.0--66.0)   60.0 (52.0--60.0)   60.0 (1.8--105.0)

###### 

Dose of irradiation (surgically treated cases)

  Dose of irradiation (Gy)   Preoperative irradiation (%)   Postoperative irradiation (%)
  -------------------------- ------------------------------ -------------------------------
  ≤29                        2 (1.0%)                       
  30--39                     34 (17.5%)                     1 (2.1%)
  40--49                     132 (68.0%)                    10 (21.3%)
  50--59                     7 (3.6%)                       12 (25.5%)
  60--69                     13 (6.7%)                      22 (46.8%)
  ≥70                                                       2 (1.1%)
  Unknown                    6 (3.1%)                       
  Total                      194                            47
  Median (min--max)          40.0 (0.0--66.0)               60.0 (30.0--79.2)

IV. Results in patients who underwent esophagectomy in 2010 {#Sec8}
===========================================================

###### 

Treatment modalities of esophagectomy

  Treatments                                                 Cases (%)
  ---------------------------------------------------------- --------------
  Esophagectomy alone                                        1463 (41.0%)
  Esophagectomy + endoscopic treatment                       83 (2.3%)
  Esophagectomy + chemoradiotherapy                          571 (16.0%)
   Concurrent chemoradiotherapy                              502 (14.1%)
   Other                                                     69 (1.9%)
  Esophagectomy + chemoradiotherapy + endoscopic treatment   13 (0.4%)
  Esophagectomy + chemotherapy                               1391 (39.0%)
   Preoperative                                              1027 (28.8%)
   Postoperative                                             183 (5.1%)
   Pre and postoperative                                     75 (2.1%)
   Recurrence                                                46 (1.3%)
   Other                                                     60 (1.7%)
  Esophagectomy + chemotherapy + endoscopic treatment        3 (0.1%)
  Esophagectomy + radiotherapy                               39 (1.1%)
   Preoperative                                              4 (0.1%)
   Postoperative                                             7 (0.2%)
   Recurrence                                                15 (0.4%)
   Other                                                     13 (0.4%)
  Esophagectomy + radiotherapy + endoscopic treatment        1 (0.0%)
  Total                                                      3564

###### 

Tumor location

  Locations         Cases (%)
  ----------------- --------------
  Cervical          116 (3.3%)
  Upper thoracic    411 (11.5%)
  Middle thoracic   1669 (46.8%)
  Lower thoracic    1054 (29.6%)
  E \> G            241 (6.8%)
  E = G             38 (1.1%)
  G \> E            27 (0.8%)
  Unknown           8 (0.2%)
  Total lesions     3564

###### 

Approaches to tumor resection

  Approaches                           Cases (%)
  ------------------------------------ --------------
  Cervical approach                    150 (4.2%)
  Right thoracotomy                    3010 (84.5%)
  Left thoracotomy                     50 (1.4%)
  Left thoracoabdominal approach       58 (1.6%)
  Laparotomy                           108 (3.0%)
  Transhiatal thoracic esophagectomy   50 (1.4%)
  Transhiatal lower esophagectomy      72 (2.0%)
  Sternotomy                           4 (0.1%)
  Others                               28 (0.8%)
  Unknown                              34 (1.0%)
  Total                                3564

###### 

Video-assisted surgery

  Video-assisted surgery                         Cases (%)
  ---------------------------------------------- --------------
  None                                           2117 (59.4%)
  Thoracoscopy                                   653 (18.3%)
  Thoracoscopy + laparoscopy                     431 (12.1%)
  Thoracoscopy + laparoscopy + mediastinoscopy   1 (0.0%)
  Thoracoscopy + laparoscopy + other             1 (0.0%)
  Laparoscopy                                    104 (2.9%)
  Laparoscopy + mediastinoscopy                  8 (0.2%)
  Laparoscopy + other                            1 (0.0%)
  Mediastinoscopy                                4 (0.1%)
  Others                                         11 (0.3%)
  Total                                          3564

###### 

Fields of lymph node dissection according to the location of the tumor

  Field of lymphadenectomy   Cervical     Upper thoracic   Middle thoracic   Lower thoracic   E \> G        E = G        G \> E       Unknown     Total
  -------------------------- ------------ ---------------- ----------------- ---------------- ------------- ------------ ------------ ----------- --------------
  None                       10 (8.6%)    13 (3.2%)        59 (3.5%)         28 (2.7%)        13 (5.4%)                               2 (25.0%)   125 (3.5%)
  C                          36 (31.0%)   10 (2.4%)        20 (1.2%)         3 (0.3%)         1 (0.4%)                                            70 (2.0%)
  C + UM                     21 (18.1%)   6 (1.5%)         3 (0.2%)          1 (0.1%)                                                             31 (0.9%)
  C + UM + MLM               2 (1.7%)     12 (2.9%)        28 (1.7%)         12 (1.1%)                                   1 (3.7%)                 55 (1.5%)
  C + UM + MLM + A           27 (23.3%)   257 (62.5%)      800 (47.9%)       367 (34.8%)      26 (10.8%)    6 (15.8%)                 1 (12.5%)   1484 (41.6%)
  C + UM + MLM + A+OT                                                        1 (0.1%)                                                             1 (0.0%)
  C + UM + A                 2 (1.7%)     1 (0.2%)         2 (0.1%)          2 (0.2%)                                                             7 (0.2%)
  C + MLM                                                  1 (0.1%)                                                                               1 (0.0%)
  C + MLM + A                3 (2.6%)     1 (0.2%)         7 (0.4%)          3 (0.3%)                                                             14 (0.4%)
  C + A                      1 (0.9%)     2 (0.5%)         4 (0.2%)          2 (0.2%)         1 (0.4%)                                            10 (0.3%)
  UM                         4 (3.4%)     3 (0.7%)         5 (0.3%)          3 (0.3%)                                                             15 (0.4%)
  UM + MLM                   1 (0.9%)     7 (1.7%)         29 (1.7%)         12 (1.1%)        1 (0.4%)                                1 (12.5%)   51 (1.4%)
  UM + MLM + A               3 (2.6%)     75 (18.2%)       627 (37.6%)       478 (45.4%)      56 (23.2%)    5 (13.2%)    1 (3.7%)     1 (12.5%)   1246 (35.0%)
  UM + A                     1 (0.9%)     4 (1.0%)         2 (0.1%)          2 (0.2%)         2 (0.8%)                                            11 (0.3%)
  MLM                                     3 (0.7%)         10 (0.6%)         14 (1.3%)        3 (1.2%)                                            30 (0.8%)
  MLM + A                    1 (0.9%)     7 (1.7%)         34 (2.0%)         102 (9.7%)       108 (44.8%)   23 (60.5%)   17 (63.0%)               292 (8.2%)
  A                          1 (0.9%)     6 (1.5%)         22 (1.3%)         12 (1.1%)        28 (11.6%)    3 (7.9%)     8 (29.6%)    1 (12.5%)   81 (2.3%)
  Unknown                    3 (2.6%)     4 (1.0%)         16 (1.0%)         12 (1.1%)        2 (0.8%)      1 (2.6%)                  2 (25.0%)   40 (1.1%)
  Total                      116          411              1669              1054             241           38           27           8           3564

*C* bilateral cervical nodes, *UM* upper mediastinal nodes, *MLM* middle-lower mediastinal nodes, *A* abdominal nodes

###### 

Reconstruction route

  Reconstruction route    Cases (%)
  ----------------------- --------------
  None                    57 (1.6%)
  Subcutaneous            302 (8.5%)
  Retrosternal            1191 (33.4%)
  Posterior mediastinal   1473 (41.3%)
  Intrathoracic           435 (12.2%)
  Cervical                50 (1.4%)
  Others                  34 (1.0%)
  Unknown                 22 (0.6%)
  Total                   3564

###### 

Organs used for reconstruction

  Organs used for reconstruction   Cases (%)
  -------------------------------- --------------
  None                             72 (2.0%)
  Whole stomach                    71 (2.0%)
  Gastric tube                     3059 (85.0%)
  Jejunum                          176 (4.9%)
  Free jejunum                     69 (1.9%)
  Colon                            114 (3.2%)
  Free colon                       10 (0.3%)
  Others                           13 (0.4%)
  Unknown                          16 (0.4%)
  Total organs                     3600
  Total cases                      3564

###### 

Histological classification

  Histological classification    Cases (%)
  ------------------------------ --------------
  Squamous cell carcinoma        3045 (86.0%)
   Squamous cell carcinoma       584 (16.5%)
   Well differentiated           566 (16.0%)
   Moderately differentiated     1445 (40.8%)
   Poorly differentiated         450 (12.7%)
  Adenocarcinoma                 161 (4.5%)
  Barrett's adenocarcinoma       71 (2.0%)
  Adenosquamous cell carcinoma   20 (0.6%)
  Mucoepidermoid carcinoma       3 (0.1%)
  Adenoid cystic carcinoma       2 (0.1%)
  Basaloid carcinoma             71 (2.0%)
  Endocrine cell carcinoma       15 (0.4%)
  Undifferentiated carcinoma     6 (0.2%)
  Other carcinoma                14 (0.4%)
  Carcinosarcoma                 18 (0.5%)
  Malignant melanoma             16 (0.5%)
  GIST                           1 (0.0%)
  Other                          33 (0.9%)
  Unknown                        66 (1.9%)
  Total                          3542

###### 

Depth of tumor invasion, pT (JES 10th)

  pT category   Cases (%)
  ------------- --------------
  pTX           25 (0.7%)
  pT0           79 (2.2%)
  pTis          25 (0.7%)
  pT1a          373 (10.5%)
  pT1b          943 (26.5%)
  pT2           450 (12.6%)
  pT3           1368 (38.4%)
  pT4           111 (3.1%)
  pT4a          34 (1.0%)
  pT4b          33 (0.9%)
  Unknown       123 (3.5%)
  Total         3564

###### 

Pathological grading of lymph node metastasis, pN (JES 10th)

  Lymph node metastasis   Cases (%)
  ----------------------- --------------
  pN0                     2079 (58.3%)
  pN1                     474 (13.3%)
  pN2                     564 (15.8%)
  pN3                     233 (6.5%)
  pN4                     149 (4.2%)
  Unknown                 65 (1.8%)
  Total                   3564

###### 

Pathological findings of lymph node metastasis, pN (UICC 7th)

  Lymph node metastasis   Cases (%)
  ----------------------- --------------
  pN0                     1571 (44.1%)
  pN1 (1--2)              956 (26.8%)
  pN2 (3--6)              623 (17.5%)
  pN3 (7--)               351 (9.8%)
  Unknown                 63 (1.8%)
  Total                   3564

Regional lymph nodes are different in JES 10th and UICC 7th

Data for Tables [23](#Tab23){ref-type="table"} and [24](#Tab24){ref-type="table"} are analyzed from different variables in the registration application

###### 

Pathological findings of distant organ metastasis, pM (JES 10th)

  Distant metastasis   Cases (%)
  -------------------- --------------
  pMX                  62 (1.7%)
  pM0                  3446 (96.7%)
  pM1                  56 (1.6%)
  Total                3564

###### 

Residual tumor

  Residual tumor   Cases (%)
  ---------------- --------------
  RX               156 (4.1%)
  R0               3345 (87.0%)
  R1               187 (4.9%)
  R2               156 (4.1%)
  Total            3844

###### 

Causes of death

  Cause of death                      Cases (%)
  ----------------------------------- --------------
  Death due to recurrence             1139 (72.8%)
  Death due to other cancer           65 (4.2%)
  Death due to other disease (rec+)   44 (2.8%)
  Death due to other disease (rec−)   179 (11.4%)
  Death due to other disease (rec?)   7 (0.4%)
  Operative death\*                   39 (2.5%)
  Postoperative hospital death\*\*    40 (2.6%)
  Unknown                             52 (3.3%)
  Total of death cases                1565 (100%)

*rec* recurrence

\* Operative death means death within 30 days after operation in or out of hospital

\*\* Hospital death is defined as death during the same hospitalization, regardless of department at time of death

Operative mortality after esophagectomy: 0.61%

Hospital mortality after esophagectomy: 4.29%
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These data were first made available on January 2017, as the Comprehensive Registry of Esophageal Cancer in Japan, 2010. Not all the pages are reprinted here.

The authors were members of the Registration Committee for Esophageal Cancer, the Japan Esophageal Society, and made great contributions to the preparation of this material.

This study was supported by Health and Labour Sciences Research Grants for Promotion of Cancer Control Programs (H26-Cancer Policy-General-014) from the Ministry of Health, Labour and Welfare of Japan.

Conflict of interest {#FPar1}
====================

All authors have nothing to disclose with regard to commercial support.
